TY - JOUR
T1 - The art of cardiovascular risk assessment
AU - Khambhati, Jay
AU - Allard-Ratick, Marc
AU - Dhindsa, Devinder
AU - Lee, Suegene
AU - Chen, John
AU - Sandesara, Pratik B.
AU - O'Neal, Wesley
AU - Quyyumi, Arshed A.
AU - Wong, Nathan D.
AU - Blumenthal, Roger S.
AU - Sperling, Laurence S.
N1 - Publisher Copyright:
© 2018 Wiley Periodicals, Inc.
PY - 2018/5
Y1 - 2018/5
N2 - Cardiovascular disease (CVD) remains the leading cause of death in the United States. Healthcare expenditures have been principally allocated toward treatment of CVD at the end of the health/disease continuum, rather than toward health promotion and disease prevention. A focused effort on both primordial and primary prevention can promote cardiovascular health and reduce the burden of CVD. Risk-factor assessment for predicting atherosclerotic CVD events serves as the foundation of preventive cardiology and has been driven by population-based scoring algorithms based on traditional risk factors. Incorporating individual nontraditional risk factors, biomarkers, and selective use of noninvasive measures may help identify more at-risk patients as well as truly low-risk individuals, allowing for better targeting of treatment intensity. Using a combination of validated population-based atherosclerotic CVD risk-assessment tools, nontraditional risk factors, social health determinants, and novel markers of atherosclerotic disease, we should be able to improve our ability to assess CVD risk. Through scientific evidence, clinical judgment, and discussion between the patient and clinician, we can implement an effective evidence-based strategy to assess and reduce CVD risk.
AB - Cardiovascular disease (CVD) remains the leading cause of death in the United States. Healthcare expenditures have been principally allocated toward treatment of CVD at the end of the health/disease continuum, rather than toward health promotion and disease prevention. A focused effort on both primordial and primary prevention can promote cardiovascular health and reduce the burden of CVD. Risk-factor assessment for predicting atherosclerotic CVD events serves as the foundation of preventive cardiology and has been driven by population-based scoring algorithms based on traditional risk factors. Incorporating individual nontraditional risk factors, biomarkers, and selective use of noninvasive measures may help identify more at-risk patients as well as truly low-risk individuals, allowing for better targeting of treatment intensity. Using a combination of validated population-based atherosclerotic CVD risk-assessment tools, nontraditional risk factors, social health determinants, and novel markers of atherosclerotic disease, we should be able to improve our ability to assess CVD risk. Through scientific evidence, clinical judgment, and discussion between the patient and clinician, we can implement an effective evidence-based strategy to assess and reduce CVD risk.
KW - General Clinical Cardiology/Adult
KW - Ischemic Heart Disease
KW - Preventive Cardiology
UR - http://www.scopus.com/inward/record.url?scp=85046788326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046788326&partnerID=8YFLogxK
U2 - 10.1002/clc.22930
DO - 10.1002/clc.22930
M3 - Review article
C2 - 29746005
AN - SCOPUS:85046788326
SN - 0160-9289
VL - 41
SP - 677
EP - 684
JO - Clinical Cardiology
JF - Clinical Cardiology
IS - 5
ER -